Logo image of PGNY

PROGYNY INC (PGNY) Stock Fundamental Analysis

NASDAQ:PGNY - Nasdaq - US74340E1038 - Common Stock - Currency: USD

21.03  -0.52 (-2.41%)

After market: 21.03 0 (0%)

Fundamental Rating

7

Overall PGNY gets a fundamental rating of 7 out of 10. We evaluated PGNY against 102 industry peers in the Health Care Providers & Services industry. PGNY has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. PGNY has a decent growth rate and is not valued too expensively. With these ratings, PGNY could be worth investigating further for quality investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

In the past year PGNY was profitable.
PGNY had a positive operating cash flow in the past year.
Each year in the past 5 years PGNY has been profitable.
PGNY had a positive operating cash flow in each of the past 5 years.
PGNY Yearly Net Income VS EBIT VS OCF VS FCFPGNY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

1.2 Ratios

PGNY has a better Return On Assets (7.19%) than 89.22% of its industry peers.
PGNY's Return On Equity of 11.24% is fine compared to the rest of the industry. PGNY outperforms 75.49% of its industry peers.
The Return On Invested Capital of PGNY (11.34%) is better than 87.25% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for PGNY is in line with the industry average of 9.62%.
The 3 year average ROIC (8.25%) for PGNY is below the current ROIC(11.34%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 7.19%
ROE 11.24%
ROIC 11.34%
ROA(3y)7.58%
ROA(5y)11.89%
ROE(3y)10.72%
ROE(5y)17.23%
ROIC(3y)8.25%
ROIC(5y)7.66%
PGNY Yearly ROA, ROE, ROICPGNY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

PGNY has a better Profit Margin (4.33%) than 74.51% of its industry peers.
In the last couple of years the Profit Margin of PGNY has declined.
With a decent Operating Margin value of 6.03%, PGNY is doing good in the industry, outperforming 62.75% of the companies in the same industry.
In the last couple of years the Operating Margin of PGNY has grown nicely.
Looking at the Gross Margin, with a value of 21.99%, PGNY is in line with its industry, outperforming 47.06% of the companies in the same industry.
PGNY's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 6.03%
PM (TTM) 4.33%
GM 21.99%
OM growth 3Y-3.61%
OM growth 5Y1.87%
PM growth 3Y-29.25%
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y1.85%
PGNY Yearly Profit, Operating, Gross MarginsPGNY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20

More info and screens

9

2. Health

2.1 Basic Checks

PGNY has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
PGNY has less shares outstanding than it did 1 year ago.
PGNY has more shares outstanding than it did 5 years ago.
PGNY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PGNY Yearly Shares OutstandingPGNY Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
PGNY Yearly Total Debt VS Total AssetsPGNY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

PGNY has an Altman-Z score of 6.95. This indicates that PGNY is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 6.95, PGNY belongs to the top of the industry, outperforming 93.14% of the companies in the same industry.
PGNY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 6.95
ROIC/WACC1.25
WACC9.05%
PGNY Yearly LT Debt VS Equity VS FCFPGNY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

PGNY has a Current Ratio of 2.39. This indicates that PGNY is financially healthy and has no problem in meeting its short term obligations.
PGNY has a Current ratio of 2.39. This is amongst the best in the industry. PGNY outperforms 83.33% of its industry peers.
PGNY has a Quick Ratio of 2.39. This indicates that PGNY is financially healthy and has no problem in meeting its short term obligations.
PGNY has a Quick ratio of 2.39. This is amongst the best in the industry. PGNY outperforms 84.31% of its industry peers.
Industry RankSector Rank
Current Ratio 2.39
Quick Ratio 2.39
PGNY Yearly Current Assets VS Current LiabilitesPGNY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

6

3. Growth

3.1 Past

PGNY shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.56%.
The Earnings Per Share has been decreasing by -4.77% on average over the past years.
The Revenue has grown by 9.46% in the past year. This is quite good.
Measured over the past years, PGNY shows a very strong growth in Revenue. The Revenue has been growing by 38.42% on average per year.
EPS 1Y (TTM)-6.56%
EPS 3Y-4.77%
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)9.46%
Revenue growth 3Y32.6%
Revenue growth 5Y38.42%
Sales Q2Q%16.53%

3.2 Future

Based on estimates for the next years, PGNY will show a very strong growth in Earnings Per Share. The EPS will grow by 31.89% on average per year.
The Revenue is expected to grow by 9.02% on average over the next years. This is quite good.
EPS Next Y4.54%
EPS Next 2Y45.87%
EPS Next 3Y41.15%
EPS Next 5Y31.89%
Revenue Next Year6.92%
Revenue Next 2Y8.96%
Revenue Next 3Y10.23%
Revenue Next 5Y9.02%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
PGNY Yearly Revenue VS EstimatesPGNY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
PGNY Yearly EPS VS EstimatesPGNY Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0.5 1 1.5 2 2.5

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 36.89, which means the current valuation is very expensive for PGNY.
Compared to the rest of the industry, the Price/Earnings ratio of PGNY is on the same level as its industry peers.
Compared to an average S&P500 Price/Earnings ratio of 26.32, PGNY is valued a bit more expensive.
With a Price/Forward Earnings ratio of 17.34, PGNY is valued on the expensive side.
Based on the Price/Forward Earnings ratio, PGNY is valued a bit cheaper than the industry average as 67.65% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 22.13. PGNY is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 36.89
Fwd PE 17.34
PGNY Price Earnings VS Forward Price EarningsPGNY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

PGNY's Enterprise Value to EBITDA is on the same level as the industry average.
Based on the Price/Free Cash Flow ratio, PGNY is valued cheaply inside the industry as 88.24% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 9.21
EV/EBITDA 18.26
PGNY Per share dataPGNY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
PGNY has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as PGNY's earnings are expected to grow with 41.15% in the coming years.
PEG (NY)8.12
PEG (5Y)N/A
EPS Next 2Y45.87%
EPS Next 3Y41.15%

More info and screens

0

5. Dividend

5.1 Amount

PGNY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROGYNY INC

NASDAQ:PGNY (6/13/2025, 8:00:01 PM)

After market: 21.03 0 (0%)

21.03

-0.52 (-2.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners98.2%
Inst Owner Change-8.73%
Ins Owners1.37%
Ins Owner Change5.13%
Market Cap1.80B
Analysts77.5
Price Target27.25 (29.58%)
Short Float %8.53%
Short Ratio5.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.62%
Min EPS beat(2)-11.77%
Max EPS beat(2)15%
EPS beat(4)1
Avg EPS beat(4)-4.37%
Min EPS beat(4)-19.12%
Max EPS beat(4)15%
EPS beat(8)5
Avg EPS beat(8)12.82%
EPS beat(12)9
Avg EPS beat(12)54.88%
EPS beat(16)13
Avg EPS beat(16)111.04%
Revenue beat(2)2
Avg Revenue beat(2)4.47%
Min Revenue beat(2)3.19%
Max Revenue beat(2)5.74%
Revenue beat(4)2
Avg Revenue beat(4)0.3%
Min Revenue beat(4)-5.35%
Max Revenue beat(4)5.74%
Revenue beat(8)4
Avg Revenue beat(8)-0.24%
Revenue beat(12)7
Avg Revenue beat(12)0.33%
Revenue beat(16)7
Avg Revenue beat(16)-0.81%
PT rev (1m)-2.09%
PT rev (3m)0.81%
EPS NQ rev (1m)-13.35%
EPS NQ rev (3m)-12.98%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.08%
Revenue NQ rev (1m)1.18%
Revenue NQ rev (3m)2.69%
Revenue NY rev (1m)0.4%
Revenue NY rev (3m)2.54%
Valuation
Industry RankSector Rank
PE 36.89
Fwd PE 17.34
P/S 1.49
P/FCF 9.21
P/OCF 8.87
P/B 3.86
P/tB 4.09
EV/EBITDA 18.26
EPS(TTM)0.57
EY2.71%
EPS(NY)1.21
Fwd EY5.77%
FCF(TTM)2.28
FCFY10.86%
OCF(TTM)2.37
OCFY11.27%
SpS14.15
BVpS5.45
TBVpS5.14
PEG (NY)8.12
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 7.19%
ROE 11.24%
ROCE 14.82%
ROIC 11.34%
ROICexc 23.6%
ROICexgc 26.56%
OM 6.03%
PM (TTM) 4.33%
GM 21.99%
FCFM 16.14%
ROA(3y)7.58%
ROA(5y)11.89%
ROE(3y)10.72%
ROE(5y)17.23%
ROIC(3y)8.25%
ROIC(5y)7.66%
ROICexc(3y)19.18%
ROICexc(5y)17.15%
ROICexgc(3y)20.6%
ROICexgc(5y)18.86%
ROCE(3y)10.79%
ROCE(5y)10.01%
ROICexcg growth 3Y11.16%
ROICexcg growth 5Y-10.91%
ROICexc growth 3Y11.54%
ROICexc growth 5Y-2.19%
OM growth 3Y-3.61%
OM growth 5Y1.87%
PM growth 3Y-29.25%
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y1.85%
F-Score7
Asset Turnover1.66
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 207.4%
Cap/Sales 0.61%
Interest Coverage 250
Cash Conversion 265.01%
Profit Quality 372.94%
Current Ratio 2.39
Quick Ratio 2.39
Altman-Z 6.95
F-Score7
WACC9.05%
ROIC/WACC1.25
Cap/Depr(3y)177.5%
Cap/Depr(5y)150.16%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.39%
Profit Quality(3y)290.66%
Profit Quality(5y)196.79%
High Growth Momentum
Growth
EPS 1Y (TTM)-6.56%
EPS 3Y-4.77%
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y4.54%
EPS Next 2Y45.87%
EPS Next 3Y41.15%
EPS Next 5Y31.89%
Revenue 1Y (TTM)9.46%
Revenue growth 3Y32.6%
Revenue growth 5Y38.42%
Sales Q2Q%16.53%
Revenue Next Year6.92%
Revenue Next 2Y8.96%
Revenue Next 3Y10.23%
Revenue Next 5Y9.02%
EBIT growth 1Y11.23%
EBIT growth 3Y27.82%
EBIT growth 5Y41.01%
EBIT Next Year26.8%
EBIT Next 3Y17.86%
EBIT Next 5Y15.2%
FCF growth 1Y79.62%
FCF growth 3Y93.67%
FCF growth 5YN/A
OCF growth 1Y80.28%
OCF growth 3Y90.18%
OCF growth 5YN/A